Terumo (4543) AI Stock Analysis

• Market Cap: ¥3.63T
• Dividend Yield: 1.18%
• Average Volume (3M): 4.13M
• Price to Earnings (P/E): 27.8
• Beta (1Y): 0.63
• Revenue Growth: 7.68%
• EPS Growth: 10.08%
• Country: JP
• Employees: 30,207
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 23.76
• Shares Outstanding: 1,480,559,700
• 10 Day Avg. Volume: 5,678,230
• 30 Day Avg. Volume: 4,132,130
• PEG Ratio: 3.37
• Price to Book (P/B): 3.03
• Price to Sales (P/S): 4.00
• P/FCF Ratio: 29.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,900.53
• Price Target Upside: 52.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 96.96
• Revenue Forecast (FY): ¥1.09T

• Rating: 73 Outperform
• Price Target: ¥2,808.00 ▲(9.92% Upside)

Terumo's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. While technical indicators suggest a neutral to slightly bearish trend, and valuation metrics indicate the stock may be overvalued, the company's robust growth and strategic initiatives provide a solid foundation for future performance.

Positive Factors

Revenue Growth

Record-high revenue indicates strong market demand and effective sales strategies, supporting long-term growth prospects.

Product Innovation

Innovative products like the Dual Sensor System enhance competitive advantage and expand market opportunities in the imaging segment.

Strategic Acquisitions

Strategic acquisitions like OrganOx bolster Terumo's portfolio, driving substantial revenue growth and enhancing market position.

Negative Factors

Tariff Impacts

Tariff impacts can erode profit margins and increase costs, posing a challenge to maintaining long-term profitability.

Temporary Costs

Temporary costs from strategic initiatives can strain short-term financial performance, requiring careful management to sustain growth.

Demand Challenges

Lower than expected demand for certain products necessitates production adjustments, impacting operational efficiency and revenue.

Terumo Business Overview & Revenue Model

Company Description

Terumo Corporation (4543) is a global medical technology company based in Japan, specializing in a wide range of healthcare products and services. The company operates primarily in two sectors: Medical Devices and Blood Management. Terumo's core offerings include vascular access devices, transfusion systems, and interventional cardiology products. The company is committed to advancing medical technology and improving patient outcomes through innovative solutions.

How the Company Makes Money

Terumo generates revenue primarily through the sale of its medical devices and related products. Key revenue streams include the sale of vascular access products, blood management systems, and interventional cardiology devices. The company benefits from strong relationships with hospitals, healthcare providers, and distributors worldwide. Additionally, Terumo invests in research and development to create new products and enhance existing offerings, which helps maintain its competitive edge in the medical technology sector. Partnerships with healthcare institutions and participation in global healthcare initiatives also contribute to its revenue growth.

Terumo Financial Statement Overview

Summary

Terumo exhibits strong financial health with impressive revenue growth and profitability. The balance sheet is solid with low leverage, and cash flows are generally robust despite recent fluctuations. The company is well-positioned in the medical instruments and supplies industry, though careful attention to cash flow trends is advisable.

Income Statement

Terumo's income statement shows strong revenue growth with a 17.1% increase in TTM, supported by a solid gross profit margin of 54.11%. The net profit margin is healthy at 11.29%, indicating effective cost management. EBIT and EBITDA margins are robust, reflecting operational efficiency. Overall, the company demonstrates strong growth and profitability.

Balance Sheet

The balance sheet is stable with a low debt-to-equity ratio of 0.16, indicating conservative leverage. Return on equity is moderate at 8.50%, suggesting efficient use of equity. The equity ratio is strong, showing a solid capital structure. However, the slight decline in equity over time could be a point of concern.

Cash Flow

Cash flow analysis reveals a slight decline in free cash flow growth, but operating cash flow remains strong with a high coverage ratio. The free cash flow to net income ratio is healthy, indicating good cash generation relative to earnings. While cash flow stability is evident, the recent dip in free cash flow growth warrants monitoring.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.04T	1.04T	921.86B	820.21B	703.30B	613.84B
Gross Profit	568.57B	560.67B	454.17B	417.37B	369.34B	326.62B
EBITDA	255.56B	246.74B	220.35B	190.39B	175.55B	153.33B
Net Income	124.93B	116.98B	106.37B	89.33B	88.81B	77.27B
Balance Sheet
Total Assets	1.80T	1.83T	1.83T	1.60T	1.47T	1.35T
Cash, Cash Equivalents and Short-Term Investments	204.29B	222.15B	206.33B	187.38B	205.31B	200.83B
Total Debt	169.85B	213.96B	268.55B	266.67B	259.01B	293.08B
Total Liabilities	430.36B	459.85B	504.31B	491.16B	461.37B	494.53B
Stockholders Equity	1.37T	1.37T	1.33T	1.11T	1.01T	856.66B
Cash Flow
Free Cash Flow	137.39B	142.19B	85.60B	64.84B	87.95B	59.17B
Operating Cash Flow	207.74B	210.80B	146.33B	117.54B	141.47B	121.48B
Investing Cash Flow	-83.66B	-82.48B	-81.47B	-59.12B	-78.45B	-85.32B
Financing Cash Flow	-101.37B	-108.77B	-62.08B	-86.56B	-70.88B	-7.44B

Terumo Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2554.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4543, the sentiment is Neutral. The current price of 2554.5 is above the 20-day moving average (MA) of 2468.40, above the 50-day MA of 2486.52, and below the 200-day MA of 2618.25, indicating a bearish trend. The MACD of -33.20 indicates Positive momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 22.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4543.

Terumo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4543	73 Outperform	¥3.63T	27.78	9.31%	1.18%	7.68%	10.08%
7733	72 Outperform	$2.13T	19.23	13.13%	1.07%	0.42%	34.76%
7747	68 Neutral	$667.11B	52.35	10.09%	0.84%	13.53%	-7.39%
7741	68 Neutral	$8.61T	41.34	20.74%	1.04%	8.83%	8.63%
8086	62 Neutral	¥242.85B	22.30	4.38%	2.03%	6.04%	733.13%
6869	60 Neutral	$1.06T	22.55	9.80%	1.74%	1.51%	-12.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Terumo Corporate Events

Terumo Revises FY2025 Financial Guidance Amid Yen Depreciation

Terumo Corporation has revised its full-year financial guidance for the fiscal year ending March 31, 2026, due to the yen’s depreciation and steady revenue growth. The company anticipates higher revenue and adjusted operating profit, but lower operating profit and profit attributable to owners due to acquisition-related expenses and business portfolio review costs.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen2729.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Corporation Reports Strong Financial Growth and Increased Dividends

Terumo Corporation reported a 5.2% increase in revenue and a significant rise in profits for the six months ending September 30, 2025, indicating strong operational performance. The company also announced an increase in dividends, reflecting confidence in continued financial growth and stability, which is likely to positively impact stakeholders and enhance its industry positioning.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen2729.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Corporation Revises Shareholder Benefit Program to Boost Engagement

Terumo Corporation announced an amendment to its Shareholder Benefit Program, effective from March 31, 2026. The changes aim to increase shareholder engagement by offering electronic coupons and exclusive benefits to long-term shareholders, thereby enhancing the investment appeal and promoting a deeper understanding of its business activities.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen2915.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.

Terumo Acquires OrganOx to Enter Organ Transplantation Sector

Terumo Corporation has announced its acquisition of OrganOx Limited for approximately USD 1.5 billion, marking its strategic entry into the organ transplantation sector. This move is expected to enhance Terumo’s business portfolio and address significant unmet medical needs by improving organ preservation and utilization rates, ultimately benefiting transplant patients and healthcare providers globally.

The most recent analyst rating on (JP:4543) stock is a Buy with a Yen3165.00 price target. To see the full list of analyst forecasts on Terumo stock, see the JP:4543 Stock Forecast page.